| Ytd | -4.12% | |
| 1y | 3.10% |
| Open | 319.50 | Prev Close | 321.35 | Low | 318.79 | High | 325.79 | Mkt Cap | 61.80B |
| Vol | 781.95K | Avg Vol | 1.32M | EPS | 13.57 | P/E | 23.87 | Forward P/E | 16.37 |
| Beta | 0.58 | Short Ratio | 3.82 | Inst. Own | 99.58% | Dividend | 2.40 | Div Yield | 0.75 |
| Ex Div Date | 08-14 | Earning | 11-04 | 50-d Avg | 317.91 | 200-d Avg | 317.71 | 1yr Est | 369.92 |
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.46% on an annualized basi
Cencora (NYSE:COR) held its third-quarter earnings conference call on Wednesday. Below is the comple
Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and raises
Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific b
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to relea
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Dire
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
Cencora NYSE: COR executives said the company expects its specialty-focused strategy to support cont
Cencora (NYSE: COR) executives highlighted the company's specialty pharmaceutical positioning, medic
Cencora NYSE: COR executives highlighted the company's specialty pharmaceutical positioning, medical
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
Corient Private Wealth LP lifted its holdings in Cencora, Inc. (NYSE: COR) by 102.9% during the seco
Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript
Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bank of America Corp DE purchased a new position in shares of Cencora, Inc. (NYSE: COR) during the s
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basi
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
RBC Capital analyst Ryan Halsted reiterates Cencora (NYSE:COR) with a Sector Perform and maintain
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs wi
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth des
Walmart agreed to pay $50 million to settle a DOJ lawsuit alleging its pharmacies unlawfully filled
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basi
RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform r
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basi
Beginning July 1, 2026, certain Walgreens volume that was being serviced by Cencora, Inc. (the "
Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the
Morgan Stanley analyst Erin Wright maintains Cencora (NYSE:COR) with a Overweight and raises the
JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price t
Weak U.S. jobs data boosts hopes for a Fed pause, sending AI chip stocks and other high-beta tech na
Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and raises
Cencora beats third-quarter earnings and revenue estimates, raised fiscal 2026 EPS guidance and main
Cencora (NYSE:COR) raises FY2026 Adj EPS guidance from $17.70-$17.90 to $17.75-$17.95 vs $17.79 anal
Cencora (NYSE:COR) reported quarterly earnings of $4.48 per share which beat the analyst consensus e
B of A Securities analyst Michael Funk maintains Cencora (NYSE:COR) with a Neutral and raises the
Barclays analyst Glen Santangelo maintains Cencora (NYSE:COR) with a Overweight and lowers the pr
The battle between Amazon.com and Walmart has produced a new leader for the Fortune 500 list for 202
CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company
U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.
U.S. stocks rebound as investors look past rising oil prices and focus on the Fed's rate decisio
COR stock dips as Cencora announces CFO James Cleary's retirement. Read the full details on the
Cramer said, although he likes Cencora, Cardinal Health Inc. has "got them all beat." Plus: